{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:25:20Z","timestamp":1790634320406,"version":"4.1.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1-2","license":[{"start":{"date-parts":[[2017,8,31]],"date-time":"2017-08-31T00:00:00Z","timestamp":1504137600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cell Biochem"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1007\/s11010-017-3145-3","type":"journal-article","created":{"date-parts":[[2017,8,31]],"date-time":"2017-08-31T05:30:14Z","timestamp":1504157414000},"page":"163-169","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Placental growth factor signaling regulates isoform splicing of vascular endothelial growth factor A in the control of lung cancer cell metastasis"],"prefix":"10.1007","volume":"439","author":[{"given":"Zanfeng","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingwei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,8,31]]},"reference":[{"key":"3145_CR1","doi-asserted-by":"publisher","first-page":"79805","DOI":"10.18632\/oncotarget.12972","volume":"7","author":"D Xue","year":"2016","unstructured":"Xue D, Yang Y, Liu Y, Wang P, Dai Y, Liu Q, Chen L, Shen J, Ju H, Li Y, Tan Z (2016) MicroRNA-206 attenuates the growth and angiogenesis in non-small cell lung cancer cells by blocking the 14-3-3zeta\/STAT3\/HIF-1alpha\/VEGF signaling. Oncotarget 7:79805\u201379813. doi:\n                        10.18632\/oncotarget.12972","journal-title":"Oncotarget"},{"key":"3145_CR2","doi-asserted-by":"publisher","first-page":"62224","DOI":"10.18632\/oncotarget.11406","volume":"7","author":"Z Li","year":"2016","unstructured":"Li Z, Guo C, Liu X, Zhou C, Zhu F, Wang X, Wang Q, Shi Y, Wang J, Zhao W, Zhang L (2016) TIPE2 suppresses angiogenesis and non-small cell lung cancer (NSCLC) invasiveness via inhibiting Rac1 activation and VEGF expression. Oncotarget 7:62224\u201362239. doi:\n                        10.18632\/oncotarget.11406","journal-title":"Oncotarget"},{"key":"3145_CR3","doi-asserted-by":"publisher","first-page":"70535","DOI":"10.18632\/oncotarget.12059","volume":"7","author":"Y Li","year":"2016","unstructured":"Li Y, Wang Y, Niu K, Chen X, Xia L, Lu D, Kong R, Chen Z, Duan Y, Sun J (2016) Clinical benefit from EGFR-TKI plus ginsenoside Rg3 in patients with advanced non-small cell lung cancer harboring EGFR active mutation. Oncotarget 7:70535\u201370545. doi:\n                        10.18632\/oncotarget.12059","journal-title":"Oncotarget"},{"key":"3145_CR4","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1161\/ATVBAHA.108.179663","volume":"29","author":"N Ferrara","year":"2009","unstructured":"Ferrara N (2009) Vascular endothelial growth factor. Arterioscler Thromb Vasc Biol 29:789\u2013791. doi:\n                        10.1161\/ATVBAHA.108.179663","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"3145_CR5","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/nm0603-669nm0603-669","volume":"9","author":"N Ferrara","year":"2003","unstructured":"Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9:669\u2013676. doi:\n                        10.1038\/nm0603-669nm0603-669","journal-title":"Nat Med"},{"key":"3145_CR6","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.cell.2007.08.038","volume":"131","author":"C Fischer","year":"2007","unstructured":"Fischer C, Jonckx B, Mazzone M, Zacchigna S, Loges S, Pattarini L, Chorianopoulos E, Liesenborghs L, Koch M, De Mol M, Autiero M, Wyns S, Plaisance S, Moons L, van Rooijen N, Giacca M, Stassen JM, Dewerchin M, Collen D, Carmeliet P (2007) Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 131:463\u2013475. doi:\n                        10.1016\/j.cell.2007.08.038","journal-title":"Cell"},{"key":"3145_CR7","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1038\/nm884nm884","volume":"9","author":"M Autiero","year":"2003","unstructured":"Autiero M, Waltenberger J, Communi D, Kranz A, Moons L, Lambrechts D, Kroll J, Plaisance S, De Mol M, Bono F, Kliche S, Fellbrich G, Ballmer-Hofer K, Maglione D, Mayr-Beyrle U, Dewerchin M, Dombrowski S, Stanimirovic D, Van Hummelen P, Dehio C, Hicklin DJ, Persico G, Herbert JM, Shibuya M, Collen D, Conway EM, Carmeliet P (2003) Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med 9:936\u2013943. doi:\n                        10.1038\/nm884nm884","journal-title":"Nat Med"},{"key":"3145_CR8","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1159\/000373990","volume":"35","author":"X Huo","year":"2015","unstructured":"Huo X, Li Y, Jiang Y, Sun X, Gu L, Guo W, Sun D (2015) Inhibition of ocular neovascularization by co-inhibition of VEGF-A and PLGF. Cell Physiol Biochem 35:1787\u20131796. doi:\n                        10.1159\/000373990","journal-title":"Cell Physiol Biochem"},{"key":"3145_CR9","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1159\/000430267","volume":"36","author":"H Jiang","year":"2015","unstructured":"Jiang H, Wu X, Wang H, Huang C, Zhang L (2015) Combined anti-PLGF and anti-endostatin treatments inhibit ocular hemangiomas. Cell Physiol Biochem 36:930\u2013936. doi:\n                        10.1159\/000430267","journal-title":"Cell Physiol Biochem"},{"key":"3145_CR10","doi-asserted-by":"publisher","first-page":"46668","DOI":"10.18632\/oncotarget.8694","volume":"7","author":"D Ribatti","year":"2016","unstructured":"Ribatti D (2016) Tumor refractoriness to anti-VEGF therapy. Oncotarget 7:46668\u201346677. doi:\n                        10.18632\/oncotarget.8694","journal-title":"Oncotarget"},{"key":"3145_CR11","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1042\/CS20050292","volume":"110","author":"DO Bates","year":"2006","unstructured":"Bates DO, MacMillan PP, Manjaly JG, Qiu Y, Hudson SJ, Bevan HS, Hunter AJ, Soothill PW, Read M, Donaldson LF, Harper SJ (2006) The endogenous anti-angiogenic family of splice variants of VEGF, VEGFxxxb, are down-regulated in pre-eclamptic placentae at term. Clin Sci (Lond) 110:575\u2013585. doi:\n                        10.1042\/CS20050292","journal-title":"Clin Sci (Lond)"},{"key":"3145_CR12","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1007\/s00125-005-1951-8","volume":"48","author":"RM Perrin","year":"2005","unstructured":"Perrin RM, Konopatskaya O, Qiu Y, Harper S, Bates DO, Churchill AJ (2005) Diabetic retinopathy is associated with a switch in splicing from anti- to pro-angiogenic isoforms of vascular endothelial growth factor. Diabetologia 48:2422\u20132427. doi:\n                        10.1007\/s00125-005-1951-8","journal-title":"Diabetologia"},{"key":"3145_CR13","first-page":"4123","volume":"62","author":"DO Bates","year":"2002","unstructured":"Bates DO, Cui TG, Doughty JM, Winkler M, Sugiono M, Shields JD, Peat D, Gillatt D, Harper SJ (2002) VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res 62:4123\u20134131","journal-title":"Cancer Res"},{"key":"3145_CR14","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1002\/ijc.23619","volume":"123","author":"R Diaz","year":"2008","unstructured":"Diaz R, Pena C, Silva J, Lorenzo Y, Garcia V, Garcia JM, Sanchez A, Espinosa P, Yuste R, Bonilla F, Dominguez G (2008) p73 Isoforms affect VEGF, VEGF165b and PEDF expression in human colorectal tumors: VEGF165b downregulation as a marker of poor prognosis. Int J Cancer 123:1060\u20131067. doi:\n                        10.1002\/ijc.23619","journal-title":"Int J Cancer"},{"key":"3145_CR15","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1038\/sj.bjc.6604309","volume":"98","author":"E Rennel","year":"2008","unstructured":"Rennel E, Waine E, Guan H, Schuler Y, Leenders W, Woolard J, Sugiono M, Gillatt D, Kleinerman E, Bates D, Harper S (2008) The endogenous anti-angiogenic VEGF isoform, VEGF165b inhibits human tumour growth in mice. Br J Cancer 98:1250\u20131257. doi:\n                        10.1038\/sj.bjc.6604309","journal-title":"Br J Cancer"},{"key":"3145_CR16","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0168-9525(01)02626-9","volume":"18","author":"JF Caceres","year":"2002","unstructured":"Caceres JF, Kornblihtt AR (2002) Alternative splicing: multiple control mechanisms and involvement in human disease. Trends Genet 18:186\u2013193","journal-title":"Trends Genet"},{"key":"3145_CR17","doi-asserted-by":"publisher","first-page":"3487","DOI":"10.1242\/jcs.016410","volume":"121","author":"DG Nowak","year":"2008","unstructured":"Nowak DG, Woolard J, Amin EM, Konopatskaya O, Saleem MA, Churchill AJ, Ladomery MR, Harper SJ, Bates DO (2008) Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors. J Cell Sci 121:3487\u20133495. doi:\n                        10.1242\/jcs.016410","journal-title":"J Cell Sci"},{"key":"3145_CR18","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1093\/jnci\/51.5.1417","volume":"51","author":"DJ Giard","year":"1973","unstructured":"Giard DJ, Aaronson SA, Todaro GJ, Arnstein P, Kersey JH, Dosik H, Parks WP (1973) In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. J Natl Cancer Inst 51:1417\u20131423","journal-title":"J Natl Cancer Inst"},{"key":"3145_CR19","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/nrclinonc.2012.120","volume":"9","author":"A Albini","year":"2012","unstructured":"Albini A, Tosetti F, Li VW, Noonan DM, Li WW (2012) Cancer prevention by targeting angiogenesis. Nat Rev Clin Oncol 9:498\u2013509. doi:\n                        10.1038\/nrclinonc.2012.120","journal-title":"Nat Rev Clin Oncol"},{"key":"3145_CR20","doi-asserted-by":"publisher","first-page":"3190","DOI":"10.1172\/JCI70212","volume":"123","author":"J Welti","year":"2013","unstructured":"Welti J, Loges S, Dimmeler S, Carmeliet P (2013) Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. J Clin Invest 123:3190\u20133200. doi:\n                        10.1172\/JCI70212","journal-title":"J Clin Invest"},{"key":"3145_CR21","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1002\/jcb.24438","volume":"114","author":"Y Yang","year":"2013","unstructured":"Yang Y, Sun M, Wang L, Jiao B (2013) HIFs, angiogenesis, and cancer. J Cell Biochem 114:967\u2013974. doi:\n                        10.1002\/jcb.24438","journal-title":"J Cell Biochem"},{"key":"3145_CR22","first-page":"4233","volume":"54","author":"A Takahashi","year":"1994","unstructured":"Takahashi A, Sasaki H, Kim SJ, Tobisu K, Kakizoe T, Tsukamoto T, Kumamoto Y, Sugimura T, Terada M (1994) Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis. Cancer Res 54:4233\u20134237","journal-title":"Cancer Res"},{"key":"3145_CR23","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3858\/emm.2012.44.1.023","volume":"44","author":"KJ Kim","year":"2012","unstructured":"Kim KJ, Cho CS, Kim WU (2012) Role of placenta growth factor in cancer and inflammation. Exp Mol Med 44:10\u201319. doi:\n                        10.3858\/emm.2012.44.1.023","journal-title":"Exp Mol Med"}],"container-title":["Molecular and Cellular Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11010-017-3145-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-017-3145-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-017-3145-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T06:57:29Z","timestamp":1517468249000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11010-017-3145-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,31]]},"references-count":23,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["3145"],"URL":"https:\/\/doi.org\/10.1007\/s11010-017-3145-3","relation":{},"ISSN":["0300-8177","1573-4919"],"issn-type":[{"value":"0300-8177","type":"print"},{"value":"1573-4919","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,31]]}}}